<DOC>
	<DOCNO>NCT02218684</DOCNO>
	<brief_summary>The trial objective investigate tolerability pharmacokinetics 80 mg telmisartan 2 , 4 6 mg lacidipine administer concurrently .</brief_summary>
	<brief_title>Tolerability Pharmacokinetics Telmisartan Combination With Lacidipine Healthy Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Lacidipine</mesh_term>
	<criteria>Healthy male caucasian subject determine result screen Written informed consent accordance Good Clinical Practice local legislation give Age &gt; = 18 &lt; = 50 year Broca &gt; = 20 % &lt; = + 20 % Any finding medical examination ( include blood pressure , pulse rate Electrocardiogram ( ECG ) deviate normal clinical relevance Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Surgery gastrointestinal tract ( except appendectomy ) Diseases central nervous system ( epilepsy ) psychiatric disorder neurologic disorder History orthostatic hypotension , faint spell blackouts Chronic relevant acute infection History allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge investigator Intake drug long halflife ( &gt; 24 hour ) ( &lt; = 1 month prior administration trial ) Use drug might influence result trial ( &lt; = 10 day prior administration trial ) Participation another trial investigational drug ( &lt; = 2 month prior administration trial ) Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) Inability refrain smoke study day Alcohol abuse ( &gt; 60g/day ) Drug abuse Blood donation &gt; 100 ml ( &lt; = 4 week prior administration trial ) Excessive physical activity ( &lt; = 10 day prior administration trial ) Any laboratory value outside reference range clinical relevance</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>